Analgesics Market Forecast by Opioids and NSAIDs Drug Class from 2024 to 2034
Analgesic Drugs are Getting Opioid-free with Novel Chemical Formulations. Pain Relief Medication Industry Players are All Set to Grab this New Opportunity
The analgesics market is on track to achieve a revenue of US$ 91.62 billion in 2024. The market share of analgesics is increasing continuously in the drugs and medication sector, which has the ability to translate into a CAGR of 4.6% during the forecast period. This promising growth of the industry is slated to culminate at a valuation of about US$ 143.65 billion by 2034.
Report Attribute
Details
Market Size (2024)
US$ 91.62 billion
Market Anticipated Forecast Value (2034)
US$ 143.65 billion
Market Projected Growth Rate (2024 to 2034)
4.6% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Analgesics Market Trends & Analysis
Rising cases of opioid dependency and the abuse of painkillers have led to the establishment of different abuse-deterrent systems and laws, which are put forward as a deterrent to the market. On the other hand, the forecast period is characterized by remunerative opportunities through technological development in the pharmaceutical industry to manufacture advanced versions of these drugs.
Analgesics Market Historical Analysis (2018 to 2023) Vs Forecast Outlook (2024 to 2034)
The market was valued at US$ 66.36 billion in 2018. The global market expanded at 5.6% CAGR over the past 5 years between 2018 and 2023. The overall market value was about US$ 87.14 billion by 2023.
Short Term (2024 to 2026): There is an expectation that the pandemic has stretched the market dynamics of pain management drugs. The pandemic has stressed healthcare systems around the world and heightened the need for advanced hospitals. Strengthening healthcare infrastructure is favoring the market to grow.
Medium Term (2027 to 2030): The presence of effective treatment options, large-scale investment in medical research and development, and the rising adoption of analgesics among different age groups is marked to drive the market.
Long Term (2031 to 2034): New pain reliever drugs are forecasted to create significant growth opportunities for market players due to the increasing demand for personalized medicine.
Find your sweet spots for generating winning opportunities in this market.
Challenges and Opportunities for Analgesics Market Growth
Rising Prevalence of Chronic Diseases
Long-term diseases, and cardiovascular disorders, in particular, contribute to industry growth. A rise in the prevalence of diseases such as cancer has also increased the number of people suffering from chronic pain.
Increasing Investment in Healthcare Infrastructure
Improving healthcare infrastructure is a significant factor influencing the growth rate of the overall market. Further, various government organizations are striving to improve healthcare infrastructure by increasing funding, which will further affect market dynamics.
Development of Drug Delivery Systems
The introduction of novel drug delivery systems has created more opportunities for market suppliers in the last few years. Further development of novel drug delivery systems and its spread in African and Asian countries has the potential to create and improve the future outlook for opioid analgesics.
The Severity of Abusive Opioids & their Misuse
Due to the severity of abusive opioids and their misuse, physicians have reduced their prescriptions for pain management, which has decreased sales globally. According to the International Association for the Study of Pain (IASP), around 20-30% of opioids prescribed for chronic pain are being misused. Besides this, as per the association, up to 10% of the total opioid consumers are addicted to them.
The Use of Biologics is on the Rise
Biotechnology is limiting the growth of the market due to the growth of biologics for treating inflammatory and neuropathic pain. Biologics are considered more effective than analgesics, which only provide effective pain relief for 50% of patients, and are therefore seeing greater use.
Comparative View of Adjacent Analgesics Market
Emerging trends in the analgesics market can be better realized through the comparative analysis of other related markets. The topical pain relief market and the opioid analgesic market are two other sectors with similar growth opportunities and challenges.
Analgesics Market:
Attributes
Analgesics Market
CAGR (2024 to 2034)
4.6%
Growth Factor
Rising prevalence of effective healthcare infrastructure
Market Opportunities
Increasing number of strategic collaborations and Research and Development activities
Market Trends
Several government initiatives to spread awareness and discourage use of non-prescribed drugs
Topical Pain Relief Market:
Attributes
Topical Pain Relief Market
CAGR (2024 to 2034)
5.3%
Growth Factor
Increasing prevalence of osteoarthritis and other bone-related conditions, such as diabetic neuropathy
Market Opportunities
Online platforms for topical therapeutics expected to offer lucrative growth prospects
Market Trends
Growth of topical pain relief industry being driven by growing demand for non-opioids
Opioid Analgesic Market:
Attributes
Opioid Analgesic Market
CAGR (2024 to 2034)
5.2%
Growth Factor
Rising prevalence of orthopedic diseases, cancer, and chronic pain among geriatric population
Market Opportunities
Manufacturers expected to reduce side effects of opioid analgesics
Market Trends
Demand fueled by rising disposable income
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Country-wise Insights
The table below lists the countries with a sizable market share and high growth opportunities.
Regional Market Comparison
CAGR (2024 to 2034)
United States
3.2%
Germany
3.4%
United Kingdom
3.1%
Thailand
5.4%
India
6.8%
Higher Product Demand in North America Driving the United States Market
Government initiatives to favor the utilization of pain relief drugs exhibit high demand, expected at 3.2% CAGR through the course of the forecast period. The pain relief medication industry is gaining prominence in the United States due to the growing percentage of people susceptible to chronic and lifestyle-related diseases.
As per the documentation in 2016 by the National Health Institute, over 20% of adults in the USA suffer from chronic pain and 8% have high-impact chronic pain. Additionally, the US Food and Drug Administration's (USFDA) approval of a strong pipeline of effective drugs is expected to support market growth.
Germany’s Pain Killer Market is Considered Lucrative
The rising number of over-the-counter (OTC) pharmacies in the country is anticipated to result in the growth of the regional market at 3.4% CAGR through 2034. The trend of self-medication in Germany is highly prevalent. Sales of non-prescription analgesics via OTC pharmacies in Germany have been characterized as one of the main drivers of the market in the country.
Growing Prominence of the United Kingdom Pain Medication Market
There has been a swift trend favoring analgesic utilization in the United Kingdom that has the potential to translate into a CAGR of 3.1% through 2034. The country is registering higher demand mostly concentrated in the older or geriatric population aiming to achieve a better quality of life.
Commercializing opioid-tolerant drugs is found to be one of the main opportunities for the United Kingdom market players in the opioid drugs sector.
Growing Pharmaceutical Industry in India Favoring Analgesic Development
The market in India is projected to expand at a CAGR of 6.8% over the projected years. According to research on analgesic utilization in public hospitals in India, the utilization of NSAIDs and opioids showed a higher trend than other types of analgesics.
For pain management, the governing body of India is encouraging doctors to prescribe non-opioid analgesics, which provides an opportunity for companies to introduce novel non-opioid drugs.
Additionally, key manufacturers are present in the market to manufacture and distribute analgesic drugs, and consumer expenditure on healthcare is increasing, factors positively impacting the market in the country.
Thailand is Emerging as a Highly Attractive Country for Global Players
Thailand is experiencing a remarkable rise in painkiller consumption resulting in a forecasted CAGR of 5.4% for the market. The introduction of non-opioid analgesics in the country is expected to promote the sales of non-steroidal anti-inflammatory drugs over the forecast period.
Category-wise Insights
Analgesics or Pain Medications are Utilized Predominantly during Surgeries
Attributes
Details
Top Pain Indication Segment
Surgical Pain
Total Market Share in 2024 to 2034
45.6%
Surgical pain is slotted in to hold a revenue share of 45.6% in 2024. The higher adoption of surgical procedures worldwide is the key reason driving the surgical pain segment. Also, the impact of the NSAIDs market on improving healthcare outcomes has leveraged the use of analgesic painkillers during surgery.
The growing prevalence of diseases requiring surgical treatment, like heart disease, cancer, stroke, and arthritis is poised to further increase the demand for painkillers in this segment.
Opioid Class Analgesic Drug is Witnessing Maximum Demand
Attributes
Details
Top Drug Class Segment
Opioids
Total Market Share in 2024
47.8%
Based on drug class, opioid is expected to be used for the production of 47.8% of the analgesics in 2024. High demand for opioid drug classes is because of the rising burden of chronic pain and inflammation incidences globally.
The controlled sales of opioid analgesics contribute to a higher market share for hospital pharmacies. Further, private and government funding for pharmaceutical manufacturing segments and Research and Development activities for developing opioid products have boosted the growth of this segment.
Competitive Landscape for Analgesics Market
Key players are focusing on novel and innovative approaches for the development of non-opioid or non-addictive formulations for pain management. Leading companies are strengthening their product portfolio and global footprint through acquisitions.
The strategy of expansion, new product launches, and approvals by key manufacturers is further strengthening their market presence. Besides these, mergers and acquisitions have emerged as key growth strategies adopted by market players.
Start-up Ecosystem
Various acquisition strategies and product launches have been employed by new market players to increase their market presence. For example, Advil Dual Action was launched by GlaxoSmithKline PLC on September 10, 2020, and consists of two or more pain-relieving ingredients such as ibuprofen and acetaminophen.
Recent Developments in the Global Analgesics Market
ZYNRELEF was launched in July 2021 by Heron Therapeutics Inc., based in the United States. Designed to provide postsurgical analgesia for up to 72 hours after a bunionectomy, inguinal herniorrhaphy, or total knee replacement, it is an extended-release product for soft tissue or periarticular application.
In October 2017, Pfizer Inc., and other leading healthcare organizations AmerisourceBergen, Blue Cross Blue Shield Association, and Prime Therapeutics joined Walgreens (the United States’ largest drugstore chain) to combat the national opioid abuse crisis by expanding the availability of safe medication disposal kiosks to an additional 900 Walgreens stores.
In May 2020, Assertio Therapeutics, Inc., based in California, merged with Zyla Life Sciences, based in Pennsylvania. The merger created a growing commercial pharmaceutical company with neurology, inflammation, and pain products.
Key Players Profiled in the Analgesics Market Report
Pfizer Inc.
Sun Pharmaceutical Industries, Inc.
Sanofi SA
AbbVie Inc. (Allergan plc)
Teva Pharmaceuticals
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
Endo Pharmaceuticals Inc.
Purdue Pharmaceuticals L.P.
Assertio Therapeutics, Inc.
Mallinckrodt Pharmaceuticals
Bayer AG
GlaxoSmithKline plc.
Bausch Health Companies Inc.
Novartis AG
Key Coverage in the Analgesics Market Report
Study on analgesics market in the United States
Emerging trends in Pain Medication
Overview of Analgesics Value Share in Pain Killers market.
Demand Analysis of Analgesic Tablets
Growth Analysis of Opioids
Key Segments Covered by Analgesics Industry Survey Report
By Drug Class:
Opioids
NSAIDs
Local Anesthetics
Acetaminophen
By Indication:
Surgical Pain
Cancer Pain
Neuropathic Pain
By Route of Administration:
Oral
Parenteral
Transdermal
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Drug Store
Clinics
Other Sales Channels
By Region:
North America
Latin America
Europe
East Asia
South Asia and Pacific
Middle East and Africa (MEA)
Frequently Asked Questions
How Big is the Analgesic Market Currently?
The market is estimated to be around US$ 91.62 billion in 2024.
What is the Growth Outlook of the Analgesic Market?
The market is set to develop at 4.6% CAGR during the forecast period.
What is the Projected Value of the Analgesic Market by 2034?
The market is predicted to be valued at US$ 143.65 billion by 2034.
Which Drug Class Dominates the Global Market?
Opioids are anticipated to account for nearly 47.8% revenue share of the global market in 2024.
Which Country has the High Growth Potential in the Market?
India is predicted to witness a CAGR of 6.8% in sales of analgesics through 2034.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Manufacturer
3.5.1.2. Mid-Level Participants (Traders)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Drug Class, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Drug Class, 2024 to 2034
5.3.1. Opioids
5.3.2. NSAIDs
5.3.3. Local Anaesthetics
5.3.4. Acetaminophen
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Indication, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Indication, 2024 to 2034
6.3.1. Surgical Pain
6.3.2. Cancer Pain
6.3.3. Neuropathic Pain
6.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Route of Administration, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Route of Administration, 2024 to 2034
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Transdermal
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Drug Store
8.3.4. Clinics
8.3.5. Others
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023
9.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Indication
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Indication
10.3.4. By Route of Administration
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Indication
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Indication
11.3.4. By Route of Administration
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Drug Class
12.2.3. By Indication
12.2.4. By Route of Administration
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Indication
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Drug Class
13.2.3. By Indication
13.2.4. By Route of Administration
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Drug Class
14.2.3. By Indication
14.2.4. By Route of Administration
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Drug Class
15.2.3. By Indication
15.2.4. By Route of Administration
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Indication
16.2.4. By Route of Administration
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2023
17.1.2.1. By Drug Class
17.1.2.2. By Indication
17.1.2.3. By Route of Administration
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2023
17.2.2.1. By Drug Class
17.2.2.2. By Indication
17.2.2.3. By Route of Administration
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2023
17.3.2.1. By Drug Class
17.3.2.2. By Indication
17.3.2.3. By Route of Administration
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2023
17.4.2.1. By Drug Class
17.4.2.2. By Indication
17.4.2.3. By Route of Administration
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2023
17.5.2.1. By Drug Class
17.5.2.2. By Indication
17.5.2.3. By Route of Administration
17.5.2.4. By Distribution Channel
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2023
17.6.2.1. By Drug Class
17.6.2.2. By Indication
17.6.2.3. By Route of Administration
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2023
17.7.2.1. By Drug Class
17.7.2.2. By Indication
17.7.2.3. By Route of Administration
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2023
17.8.2.1. By Drug Class
17.8.2.2. By Indication
17.8.2.3. By Route of Administration
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2023
17.9.2.1. By Drug Class
17.9.2.2. By Indication
17.9.2.3. By Route of Administration
17.9.2.4. By Distribution Channel
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2023
17.10.2.1. By Drug Class
17.10.2.2. By Indication
17.10.2.3. By Route of Administration
17.10.2.4. By Distribution Channel
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2023
17.11.2.1. By Drug Class
17.11.2.2. By Indication
17.11.2.3. By Route of Administration
17.11.2.4. By Distribution Channel
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2023
17.12.2.1. By Drug Class
17.12.2.2. By Indication
17.12.2.3. By Route of Administration
17.12.2.4. By Distribution Channel
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2023
17.13.2.1. By Drug Class
17.13.2.2. By Indication
17.13.2.3. By Route of Administration
17.13.2.4. By Distribution Channel
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2023
17.14.2.1. By Drug Class
17.14.2.2. By Indication
17.14.2.3. By Route of Administration
17.14.2.4. By Distribution Channel
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2023
17.15.2.1. By Drug Class
17.15.2.2. By Indication
17.15.2.3. By Route of Administration
17.15.2.4. By Distribution Channel
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2023
17.16.2.1. By Drug Class
17.16.2.2. By Indication
17.16.2.3. By Route of Administration
17.16.2.4. By Distribution Channel
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2023
17.17.2.1. By Drug Class
17.17.2.2. By Indication
17.17.2.3. By Route of Administration
17.17.2.4. By Distribution Channel
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2023
17.18.2.1. By Drug Class
17.18.2.2. By Indication
17.18.2.3. By Route of Administration
17.18.2.4. By Distribution Channel
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2023
17.19.2.1. By Drug Class
17.19.2.2. By Indication
17.19.2.3. By Route of Administration
17.19.2.4. By Distribution Channel
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2023
17.20.2.1. By Drug Class
17.20.2.2. By Indication
17.20.2.3. By Route of Administration
17.20.2.4. By Distribution Channel
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2023
17.21.2.1. By Drug Class
17.21.2.2. By Indication
17.21.2.3. By Route of Administration
17.21.2.4. By Distribution Channel
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2023
17.22.2.1. By Drug Class
17.22.2.2. By Indication
17.22.2.3. By Route of Administration
17.22.2.4. By Distribution Channel
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2023
17.23.2.1. By Drug Class
17.23.2.2. By Indication
17.23.2.3. By Route of Administration
17.23.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Pfizer Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.1.5.2. Product Strategy
19.1.1.5.3. Channel Strategy
19.1.2. Sun Pharmaceutical Industries, Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.2.5.2. Product Strategy
19.1.2.5.3. Channel Strategy
19.1.3. Mallinckrodt Pharmaceuticals
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.3.5.2. Product Strategy
19.1.3.5.3. Channel Strategy
19.1.4. AbbVie Inc. (Allergan plc)
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.4.5.2. Product Strategy
19.1.4.5.3. Channel Strategy
19.1.5. Teva Pharmaceuticals
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.5.5.2. Product Strategy
19.1.5.5.3. Channel Strategy
19.1.6. Boehringer Ingelheim International GmbH
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.6.5.2. Product Strategy
19.1.6.5.3. Channel Strategy
19.1.7. Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.7.5.2. Product Strategy
19.1.7.5.3. Channel Strategy
19.1.8. Endo Pharmaceuticals Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.8.5.2. Product Strategy
19.1.8.5.3. Channel Strategy
19.1.9. Purdue Pharmaceuticals L.P.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.9.5.2. Product Strategy
19.1.9.5.3. Channel Strategy
19.1.10. Assertio Therapeutics, Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.10.5.2. Product Strategy
19.1.10.5.3. Channel Strategy
19.1.11. Bayer AG
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.11.5.2. Product Strategy
19.1.11.5.3. Channel Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Volume (Unit Pack) Forecast by Region, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 4: Global Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 5: Global Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 6: Global Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 7: Global Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 8: Global Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 9: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 10: Global Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 11: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 12: North America Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 13: North America Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 14: North America Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 15: North America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 16: North America Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 17: North America Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 18: North America Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 19: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 20: North America Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 21: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 22: Latin America Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 23: Latin America Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 24: Latin America Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 25: Latin America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 26: Latin America Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 27: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 28: Latin America Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 29: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 30: Latin America Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 31: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 32: Western Europe Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 33: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 34: Western Europe Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 35: Western Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 36: Western Europe Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 37: Western Europe Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 38: Western Europe Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 39: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 40: Western Europe Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 41: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 42: Eastern Europe Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 43: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 44: Eastern Europe Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 45: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 46: Eastern Europe Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 47: Eastern Europe Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 48: Eastern Europe Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 49: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 50: Eastern Europe Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 51: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 52: South Asia and Pacific Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 53: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 54: South Asia and Pacific Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 55: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 56: South Asia and Pacific Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 57: South Asia and Pacific Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 58: South Asia and Pacific Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 59: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 60: South Asia and Pacific Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 61: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 62: East Asia Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 63: East Asia Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 64: East Asia Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 65: East Asia Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 66: East Asia Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 67: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 68: East Asia Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 69: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 70: East Asia Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 71: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 72: Middle East and Africa Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 73: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2019 to 2034
Table 74: Middle East and Africa Market Volume (Unit Pack) Forecast by Drug Class, 2019 to 2034
Table 75: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 76: Middle East and Africa Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 77: Middle East and Africa Market Value (US$ Million) Forecast by Route of Administration, 2019 to 2034
Table 78: Middle East and Africa Market Volume (Unit Pack) Forecast by Route of Administration, 2019 to 2034
Table 79: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 80: Middle East and Africa Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Indication, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 5: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 7: Global Market Volume (Unit Pack) Analysis by Region, 2019 to 2034
Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 10: Global Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 11: Global Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 14: Global Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 15: Global Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 16: Global Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 17: Global Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 18: Global Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 19: Global Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 20: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 21: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 22: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 23: Global Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 24: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 25: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 26: Global Market Attractiveness by Drug Class, 2024 to 2034
Figure 27: Global Market Attractiveness by Indication, 2024 to 2034
Figure 28: Global Market Attractiveness by Route of Administration, 2024 to 2034
Figure 29: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 30: Global Market Attractiveness by Region, 2024 to 2034
Figure 31: North America Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 32: North America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 33: North America Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 34: North America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 35: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 36: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 37: North America Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 40: North America Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 41: North America Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 42: North America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 43: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 44: North America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 45: North America Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 46: North America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 47: North America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 48: North America Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 49: North America Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 50: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 51: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 52: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 53: North America Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 54: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 55: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 56: North America Market Attractiveness by Drug Class, 2024 to 2034
Figure 57: North America Market Attractiveness by Indication, 2024 to 2034
Figure 58: North America Market Attractiveness by Route of Administration, 2024 to 2034
Figure 59: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 60: North America Market Attractiveness by Country, 2024 to 2034
Figure 61: Latin America Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 62: Latin America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 63: Latin America Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 64: Latin America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 65: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 66: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 67: Latin America Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 70: Latin America Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 71: Latin America Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 72: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 73: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 74: Latin America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 75: Latin America Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 76: Latin America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 77: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 78: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 79: Latin America Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 80: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 81: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 82: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 83: Latin America Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 84: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 85: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 86: Latin America Market Attractiveness by Drug Class, 2024 to 2034
Figure 87: Latin America Market Attractiveness by Indication, 2024 to 2034
Figure 88: Latin America Market Attractiveness by Route of Administration, 2024 to 2034
Figure 89: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 90: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 91: Western Europe Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 92: Western Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 93: Western Europe Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 94: Western Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 95: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 96: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 97: Western Europe Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 98: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 99: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 100: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 101: Western Europe Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 102: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 103: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 104: Western Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 105: Western Europe Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 106: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 107: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 108: Western Europe Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 109: Western Europe Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 110: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 111: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 112: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 113: Western Europe Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 114: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 115: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 116: Western Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 117: Western Europe Market Attractiveness by Indication, 2024 to 2034
Figure 118: Western Europe Market Attractiveness by Route of Administration, 2024 to 2034
Figure 119: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 120: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 121: Eastern Europe Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 122: Eastern Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 123: Eastern Europe Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 124: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 125: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 126: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 127: Eastern Europe Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 128: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 129: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 130: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 131: Eastern Europe Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 132: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 133: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 134: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 135: Eastern Europe Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 136: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 137: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 138: Eastern Europe Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 139: Eastern Europe Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 140: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 141: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 142: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 143: Eastern Europe Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 144: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 145: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 146: Eastern Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 147: Eastern Europe Market Attractiveness by Indication, 2024 to 2034
Figure 148: Eastern Europe Market Attractiveness by Route of Administration, 2024 to 2034
Figure 149: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 150: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 151: South Asia and Pacific Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 152: South Asia and Pacific Market Value (US$ Million) by Indication, 2024 to 2034
Figure 153: South Asia and Pacific Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 154: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 155: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 156: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 157: South Asia and Pacific Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 158: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 159: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 160: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 161: South Asia and Pacific Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 162: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 163: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 164: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 165: South Asia and Pacific Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 166: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 167: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 168: South Asia and Pacific Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 169: South Asia and Pacific Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 170: South Asia and Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 171: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 172: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 173: South Asia and Pacific Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 174: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 175: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 176: South Asia and Pacific Market Attractiveness by Drug Class, 2024 to 2034
Figure 177: South Asia and Pacific Market Attractiveness by Indication, 2024 to 2034
Figure 178: South Asia and Pacific Market Attractiveness by Route of Administration, 2024 to 2034
Figure 179: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 180: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 181: East Asia Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 182: East Asia Market Value (US$ Million) by Indication, 2024 to 2034
Figure 183: East Asia Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 184: East Asia Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 185: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 186: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 187: East Asia Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 188: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 189: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 190: East Asia Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 191: East Asia Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 192: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 193: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 194: East Asia Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 195: East Asia Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 196: East Asia Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 197: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 198: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 199: East Asia Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 200: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 201: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 202: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 203: East Asia Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 204: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 205: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 206: East Asia Market Attractiveness by Drug Class, 2024 to 2034
Figure 207: East Asia Market Attractiveness by Indication, 2024 to 2034
Figure 208: East Asia Market Attractiveness by Route of Administration, 2024 to 2034
Figure 209: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 210: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 211: Middle East and Africa Market Value (US$ Million) by Drug Class, 2024 to 2034
Figure 212: Middle East and Africa Market Value (US$ Million) by Indication, 2024 to 2034
Figure 213: Middle East and Africa Market Value (US$ Million) by Route of Administration, 2024 to 2034
Figure 214: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 215: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 216: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 217: Middle East and Africa Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 218: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 219: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 220: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2019 to 2034
Figure 221: Middle East and Africa Market Volume (Unit Pack) Analysis by Drug Class, 2019 to 2034
Figure 222: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 223: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 224: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 225: Middle East and Africa Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 226: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 227: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 228: Middle East and Africa Market Value (US$ Million) Analysis by Route of Administration, 2019 to 2034
Figure 229: Middle East and Africa Market Volume (Unit Pack) Analysis by Route of Administration, 2019 to 2034
Figure 230: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2024 to 2034
Figure 231: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2024 to 2034
Figure 232: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 233: Middle East and Africa Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 234: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 235: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 236: Middle East and Africa Market Attractiveness by Drug Class, 2024 to 2034
Figure 237: Middle East and Africa Market Attractiveness by Indication, 2024 to 2034
Figure 238: Middle East and Africa Market Attractiveness by Route of Administration, 2024 to 2034
Figure 239: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 240: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
